|
112 |
Sterilisation Processes – Requirements and Definitions
|
관리자 |
2025-04-01 |
1,335 |
|
111 |
How to Implement Quality Oversight at Shop Floor Level
|
관리자 |
2025-04-01 |
886 |
|
110 |
Quality Risk Management: What’s new in ICH Q9(R1)?
|
관리자 |
2025-04-01 |
1,304 |
|
109 |
FDA issues Warning Letter due to GMP Violations at Chinese Drug Manufacturer
|
관리자 |
2025-04-01 |
699 |
|
108 |
A Risk-based Approach To Filter Integrity Testing Annex 1 Requirements For Biologics DS
|
관리자 |
2025-02-28 |
1,185 |
|
107 |
Pharmaceutical stability testing: An overview of stability
|
관리자 |
2025-02-28 |
1,932 |
|
106 |
2024 Trends In FDA Observations For Sterile Drug Manufacturers
|
관리자 |
2025-02-28 |
838 |
|
105 |
Ensuring Repeatable, Viable Surface Sampling In Aseptic Settings
|
관리자 |
2025-02-28 |
854 |
|
104 |
Incubating settle plates: Understanding growth patterns and when things are going wrong
|
관리자 |
2025-02-03 |
1,245 |
|
103 |
11 Key Contributing Factors For Maintaining Sterility Assurance
|
관리자 |
2025-02-03 |
2,289 |
